Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 21;9(29):eadf7195. doi: 10.1126/sciadv.adf7195

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.

PMC Copyright notice

Fig. 7. — (A) Ovarian HGSC PDX-3008 xenografts (BRCA^WT, olaparib-naive tumors) were treated with olaparib (n = 6), mifepristone (n = 7), vehicle (n = 5), or olaparib in combination with mifepristone (n = 7) for 60 days. The left shows the mean tumor volume in the xenograft-bearing mice at the indicated times; the right shows the tumor mass after 60 days of treatment. Mifepristone monotherapy and mifepristone/olaparib treatment significantly suppressed tumor growth compared with vehicle (two-way ANOVA, ****P < 0.0001). Tumors treated with mifepristone alone (Welch’s t test, ***P = 0.0002) and those treated with mifepristone/olaparib (****P < 0.0001) had significantly smaller masses at harvest than did vehicle-treated tumors. Error bars indicate SD. (B) Olaparib-resistant BRCA^WT ovarian HGSC PDX-2445 xenografts were treated with olaparib (n = 7), mifepristone (n = 5), vehicle (n = 9), or mifepristone/olaparib (n = 8) for 60 days. Both mifepristone monotherapy (two-way ANOVA, ****P < 0.0001) and mifepristone/olaparib combination therapy (****P < 0.0001) significantly suppressed tumor growth compared with vehicle treatment. Tumors treated with mifepristone monotherapy (Welch’s t test, **P = 0.0061) and mifepristone/olaparib combination therapy (*P = 0.0257) had significantly smaller masses at harvest (60 days after treatment) than did vehicle-treated tumors. Error bars indicate SD. (C) Olaparib-resistant BRCA^WT ovarian HGSC PDX-2428 xenografts were treated with olaparib (n = 8), mifepristone (n = 8), vehicle (n = 8), or mifepristone/olaparib (n = 7) for 53 days. Both mifepristone monotherapy (two-way ANOVA, ****P < 0.0001) and mifepristone/olaparib combination treatment (****P < 0.0001) significantly suppressed tumor growth compared with vehicle treatment. Tumors treated with mifepristone monotherapy (Welch’s t test, ****P < 0.0001) and mifepristone/olaparib combination therapy (***P = 0.0006) had significantly smaller masses at harvest than did vehicle-treated tumors. Error bars indicate SD. ns, not significant.